drugset / Trial / NCT07147426
Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to explore the optimal course of neoadjuvant immunotherapy for HNSCC by comparing the efficacy and safety of 4 cycles and 2 cycles of neoadjuvant tislelizumab combined with chemotherapy.
Timeline
- Start
- 2025-09-20
- Primary completion
- 2026-10-20
- Completion
- 2028-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |